CSL Ltd

CSL: XASX (AUS)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|&GLOCK|ZS@%kLOCK|JC#@&J

CSL: Plasma Efficiencies on Track, but Seqirus Disappoints

CSL cut its fiscal 2026 guidance for revenue and net profit after tax before amortization growth to 3% and 6% at the midpoint, respectively, from 5% and 9%. This was driven by declines in US immunization, with the firm also delaying its plan to demerge the Seqirus vaccines arm. Shares fell 15%.

Sponsor Center